Nls pharmaceutics ceo issues letter to shareholders

Zurich , march 10, 2025 /prnewswire/ -- nls pharmaceutics ltd. (nasdaq: nlsp), a swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (cns) disorders, today issued a letter to its shareholders.

NLSP Ratings Summary

NLSP Quant Ranking